The use of CytoSorb® in a prasugrel‐loaded patient undergoing emergent coronary artery bypass graft surgery

Patients with acute coronary syndrome (ACS), failed percutaneous coronary intervention (PCI) and with an indication for emergent coronary artery bypass graft surgery (CABG) are at an increased risk of perioperative bleeding. Integration of the CytoSorb® (CS) adsorber into the cardiopulmonary bypass...

Full description

Saved in:
Bibliographic Details
Published in:Clinical case reports Vol. 11; no. 3; pp. e6990 - n/a
Main Authors: Moresco, Erich, Dejaco, Hannes, Humbert, Volker, Thoma, Matthias
Format: Journal Article
Language:English
Published: England John Wiley & Sons, Inc 01-03-2023
John Wiley and Sons Inc
Wiley
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with acute coronary syndrome (ACS), failed percutaneous coronary intervention (PCI) and with an indication for emergent coronary artery bypass graft surgery (CABG) are at an increased risk of perioperative bleeding. Integration of the CytoSorb® (CS) adsorber into the cardiopulmonary bypass appears to bind prasugrel and minimize the risk of perioperative bleeding. Intraoperative use of CytoSorb hemoadsorption therapy in prasugrel‐loaded patients undergoing emergency cardiac surgery might be an effective option to reduce the risk of bleeding complications. Further investigations, however, are needed for a better understanding of the precise role of the adsorber in this setting.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Report-1
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.6990